Xerava Injection, Powder, Lyophilized, For Solution
NDC Package 71773-050-12

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Xerava (eravacycline) injection is eravacycline is used to treat certain abdominal infections (such as appendicitis, diverticulitis, gastric/intestinal perforation). This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Tetraphase Pharmaceuticals, Inc., this product is identified by NDC 71773-050 and is authorized under FDA application NDA211109.

Identification & Billing

NDC Package Code
71773-050-12
Package Description
12 VIAL, GLASS in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS
Product Code
11-Digit Billing Format
71773005012
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
12 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Xerava
Non-Proprietary Name
Eravacycline
Substance Name
Eravacycline Dihydrochloride
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Usage Information
Eravacycline is used to treat certain abdominal infections (such as appendicitis, diverticulitis, gastric/intestinal perforation). This medication belongs to a class of drugs known as tetracycline antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Regulatory & Marketing

Labeler Name
Tetraphase Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA211109
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
09-10-2018
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Source: PDAC
INJECTION, ERAVACYCLINE, 1 MG
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (71773-050). Click a package code to view its specific billing and regulatory data.

1 VIAL, GLASS in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71773-050-12 identifies a specific commercial package of 12 vial, glass in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, glass of Xerava, a human prescription drug labeled by Tetraphase Pharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 12 billable units per package. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains eravacycline dihydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Tetraphase Pharmaceuticals, Inc. on September 10, 2018. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Eravacycline is used to treat certain abdominal infections (such as appendicitis, diverticulitis, gastric/intestinal perforation). This medication belongs to a class of drugs known as tetracycline antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

How is this Tetraphase Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71773005012. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 12 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71773-050-12
11-Digit CMS (5-4-2)
71773-0050-12

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.